Clinical Trial Update: Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluated simvastatin plus rifaximin in decompensated cirrhosis to prevent acute-on-chronic liver failure (ACLF).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• On Chronic Liver Failure

Drugs mentioned

• Rifaximin (rifaximin)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Judit Pich | Conditions: Liver Cirrhoses | Phase 2, Phase 3 | Status: COMPLETED